Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depressive Disorder, Anxiety Disorders, ...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study compares the effects of two different couple therapy approaches-Brief Psychoanalytic Couple Therapy (BPCT) and Emotionally Focused Therapy (EFT)-on reducing relationship problems and emotional symptoms like depression and anxiety. Many couples struggle with emotional distance, repeated arguments, and dissatisfaction in their relationships. While EFT is a widely used and research-supported therapy that focuses on rebuilding emotional bonds, BPCT is a less-studied method that aims to help couples understand how early relationship experiences and unconscious patterns affect their current interactions. The purpose of this study is to find out whether one of these therapies is more effective than the other in improving relationship satisfaction and reducing emotional distress. The study also looks at changes in how people regulate their emotions and how secure they feel in their relationships after therapy. In this randomized controlled trial, 60 heterosexual couples experiencing relationship distress and symptoms of anxiety or depression will be randomly assigned to one of three groups: BPCT group - couples receive weekly online therapy focusing on deep emotional and psychological patterns in their relationship. EFT group - couples receive weekly online therapy focusing on emotional connection and improving communication. Waitlist control group - couples do not receive therapy during the study but will be offered therapy afterward. Each therapy lasts 12 weeks, and follow-up assessments will be conducted up to 6 months after therapy ends. Data will be collected before, during, and after treatment using questionnaires that measure relationship satisfaction, depression, anxiety, emotional regulation, and attachment style. The results of this study will help determine which type of therapy is more beneficial for couples experiencing emotional and relational difficulties and may provide important insights for mental health professionals working with distressed couples.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Brief Psychoanalytic Couple Therapy — Brief Psychoanalytic Couple Therapy (BPCT) consists of 12 weekly online sessions (50 minutes each) focused on uncovering unconscious relational dynamics, symbolic conflict meanings, and early attachment schemas. Techniques include relational interpretations, exploration of projective identification and transference, and analysis of emotional defenses. Therapists maintain a neutral, reflective stance to promote insight and self-awareness within the couple dynamic.
  • Behavioral: Emotionally Focused Therapy — Emotionally Focused Therapy (EFT) involves 12 weekly online sessions (50 minutes each) focusing on repairing emotional bonds and enhancing attachment security. The intervention targets maladaptive emotional interaction cycles and promotes the expression of primary emotions and attachment needs. Therapists actively guide couples through restructuring emotional responses and rebuilding secure, responsive communication patterns.

Primary Outcomes

  • Change in Relationship Satisfaction (DAS-32) (Baseline, Week 6, Week 12, and 6-month Follow-up)
  • Change in Depressive Symptoms (BDI-II) (Baseline, Week 6, Week 12, and 6-month Follow-up)
  • Change in Anxiety Symptoms (BAI) (Baseline, Week 6, Week 12, and 6-month Follow-up)
  • Change in Emotion Dysregulation (DERS) (Baseline, Week 12, and 6-month Follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-01
Completion: 2026-07-15
Eligibility
Age: 24 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beykoz University
Collaborators: Istanbul Nisantasi University, Uskudar University
Principal Investigators:
  • Gökben Hızlı Sayar, Professor (STUDY_CHAIR) - Üsküdar University
  • Metin Çınaroğlu, Phd (STUDY_DIRECTOR) - İstanbul Nişantaşı University
Contact Information
Study Contact:
Eda Yılmazer, Phd
+905322575880
edayilmazer@beykoz.edu.tr
Metin Çınaroğlu, Phd
+905324732070
metin.cinaroglu@nisantasi.edu.tr
Eda Yılmazer, Phd
+905324732070
edayilmazer@beykoz.edu.tr
Beykoz University
Interventions
  • Behavioral: Brief Psychoanalytic Couple Therapy — Brief Psychoanalytic Couple Therapy (BPCT) consists of 12 weekly online sessions (50 minutes each) focused on uncovering unconscious relational dynamics, symbolic conflict meanings, and early attachment schemas. Techniques include relational interpretations, exploration of projective identification and transference, and analysis of emotional defenses. Therapists maintain a neutral, reflective stance to promote insight and self-awareness within the couple dynamic.
  • Behavioral: Emotionally Focused Therapy — Emotionally Focused Therapy (EFT) involves 12 weekly online sessions (50 minutes each) focusing on repairing emotional bonds and enhancing attachment security. The intervention targets maladaptive emotional interaction cycles and promotes the expression of primary emotions and attachment needs. Therapists actively guide couples through restructuring emotional responses and rebuilding secure, responsive communication patterns.
Study Locations (1 sites)
Beykoz University, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Heterosexual couples (both partners must participate) * Age between 24 and 65 years * Minimum 2 years of relationship duration * At least one partner scoring ≤ 30 on the Dyadic Adjustment Scale (DAS-32), indicating clinically significant relationship distress * At least one partner scoring in the mild, moderate, or severe range on the Beck Depression Inventory-II (BDI-II) or Beck Anxiety Inventory (BAI) Exclusion Criteria: * Current participation in individual or couple psychotherapy * Use of psychiatric medication during the past 3 months * Presence of severe psychiatric disorders (e.g., psychosis, bipolar disorder) * History or presence of physical or severe psychological partner violence, assessed via Conflict Tactics Scale (CTS-2) * Active substance use disorder within the past 6 months

Healthy Living Anson Study

NCT07126587
Recruiting
Conditions Obesity (Disorder), Diabetes Type 2, Hea...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized delayed control intervention research study is to see if participants who receive education and healthy prepared meals improve the quality of their diet compared to participants who receive only physical activity education and coaching.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Nutrition Education and Food Delivery — Healthy frozen meals, produce boxes, and nutrition counseling
  • Behavioral: Physical Activity Comparator — Physical activity counseling, mHealth text messaging

Primary Outcomes

  • Med-South Dietary Risk Assessment Score (Baseline, Midpoint (Month 4), Endpoint (up to Month 10))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-24
Completion: 2028-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: Westat, National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Anissa I Vines, MS, PhD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Anissa I Vines, MS, PhD
19198431210
avines@email.unc.edu
Interventions
  • Behavioral: Nutrition Education and Food Delivery — Healthy frozen meals, produce boxes, and nutrition counseling
  • Behavioral: Physical Activity Comparator — Physical activity counseling, mHealth text messaging
Study Locations (1 sites)
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria: * Potential participants must be a resident of Anson County. * At least 18 years of age. * Have or be at risk for a chronic disease. * Ability to make own dietary decisions. * Ability to travel to a central Anson County location for data collection and group class sessions. * Ability and willingness to try the prepared meals. * Ability to store 10 frozen meals in a freezer. * Ability to communicate in English * No dietary restrictions or food allergies such that a Mediterranean diet is not appropriate.
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Phase PHASE2
Enrollment 56
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus QL1706 (iparomlimab/tuvonralimab) in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) — QL1706 will be administered by IV, 5 mg/kg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
  • Drug: Lenvatinib — Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
  • Procedure: cryoablation — Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Lenvatinib plus QL1706 will be administered 1-3 days after cryoablation.

Primary Outcomes

  • Objective Response Rate (ORR) according to RECIST 1.1 (max 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-20
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Peng Wang, MD
86-21-64041990
peng_wang@fudan.edu.cn
Peng Wang, MD
+86021-64041990
peng_wang@fudan.edu.cn
Zhongshan Hospital, Fudan University
Interventions
  • Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) — QL1706 will be administered by IV, 5 mg/kg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
  • Drug: Lenvatinib — Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
  • Procedure: cryoablation — Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Lenvatinib plus QL1706 will be administered 1-3 days after cryoablation.
Study Locations (1 sites)
Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: * Written informed consent obtained. * Age ≥ 18 years at time of study entry. * Participants must have unresectable or metastatic histologically or cytologically confirmed intrahepatic cholangiocarcinoma * Participants must have failed 1 line of systemic regimens for advanced cholangiocarcinoma due to disease progression or toxicity. Cohort A must have progressed after GemCis plus PD1/PD-L1 inhibitor. Cohort B must have progressed after GemCis plus PD1/PD-L1 inhibitor and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors. * At least one measurable site of disease as defined by RECIST criteria with spiral CT scan or MRI. * Performance status (PS) ≤ 2 (ECOG scale). * Life expectancy of at least 12 weeks. * Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count ≥ 1,500/L, platelets ≥75 x103/L; Total bilirubin ≤ 3x upper normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) ≤ 5 x upper normal limit (ULN); International normalized ratio (INR) ≤1.25; Albumin ≥ 31 g/dL; Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30 mL/min (if using the Cockcroft-Gault formula ) * Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial. * Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, adherence to contraceptive measures, scheduled visits and examinations including follow up. Exclusion Criteria: * History of cardiac disease, including clinically significant gastrointestinal bleeding within 4 weeks prior to start of study treatment * Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months Prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein. * Prior treatment with cryoablation. * RFA and resection administered less than 4 weeks prior to study treatment start. * Radiotherapy administered less than 4 weeks prior to study treatment start. * Major surgery within 4 weeks of starting the study treatment OR subjects who have not recovered from effects of major surgery. * Patients with second primary cancer, except adequately treated basal skin cancer or carcinoma in-situ of the cervix. * Immunocompromised patients, e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV). * Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is longer. * Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study Treatment or interpretation of patient safety or study results, including but not limited to: a) history of interstitial lung disease b) Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) coinfection (i.e double infection) c) known acute or chronic pancreatitis d) active tuberculosis e) any other active infection (viral, fungal or bacterial) requiring systemic therapy f) history of allogeneic tissue/solid organ transplant g) diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatment. h) Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Exceptions: Subjects with vitiligo, hypothyroidism, diabetes mellitus type I or resolved childhood asthma/atopy are an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with Hashimoto thyroiditis, hypothyroidism stable on hormone replacement or psoriasis not requiring treatment are not excluded from the study. i) Live vaccine within 30 days prior to the first dose of treatment or during study treatment. j) History or clinical evidence of Central Nervous System (CNS) metastases Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria: I. are asymptomatic and II. have no requirement for steroids 6 weeks prior to start of treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS * Medication that is known to interfere with any of the agents applied in the trial. * Any other efficacious cancer treatment except protocol specified treatment at study start. * Patient has received any other investigational product within 28 days of study entry. * Prior therapy with an anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor (TNFR) family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). * Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). \[Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner\]. Women of childbearing potential must have a negative pregnancy test (serum β-HCG) at screening. * Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
Conditions Depression
Phase NA
Enrollment 192
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if a medical-social collaboration model works to reduce depressive symptoms in middle-aged and older adults with depressive symptoms who are waiting for their first psychiatric appointment. Secondary outcomes of the study include reduced anxiety symptoms, reduced loneliness, reduced rumination, reduced self-criticism, improved self-reassurance, improved resilience, improved self-efficacy, improved health-related quality of life, as well as improved quality-adjusted life years, and reduced healthcare service utilisation. Researchers will compare a medical-social collaboration model to a self-management booklet. Participants will: * Receive CBT-based stepped-care interventions through the medical-social collaboration model or a self-management booklet. * Complete a survey about their mental health and service use every three months until their first psychiatric appointment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive behavioural therapy-based stepped-care intervention — After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]). Mild symptoms (PHQ-9=5-9): 6 weekly low intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderate symptoms (PHQ-9=10-14): 6 weekly high intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderately severe symptoms (PHQ-9≥15): high intensity individual or group CBT-based intervention. Trained peer supporters will be matched to participants to walk them through the process with regular follow-up.
  • Other: Self-management booklet — The booklet incorporates components of behavioural activation, which encourages participants to engage in meaningful activities in daily life to change their mood. Trained research assistants will regularly check in with the participants to monitor their depressive symptoms.

Primary Outcomes

  • Changes in Depressive Symptoms (Baseline, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-20
Completion: 2027-06
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: true
Enrollment: 192 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: Hospital Authority Hong Kong West Cluster, Kowloon Hospital, Hong Kong, Pamela Youde Nethersole Eastern Hospital, United Christian Hospital, Kwai Chung Hospital, Castle Peak Hospital
Principal Investigators:
  • Terry YS Lum, PhD (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
  • Gloria HY Wong, PhD (PRINCIPAL_INVESTIGATOR) - University of Reading
  • Wai Chi Chan, MBChB (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
Contact Information
Study Contact:
Yao Du, PhD
852-39175594
yaodu@hku.hk
Walker SH Au
ashwalk@hku.hk
Yao Du, PhD
852-39175594
yaodu@hku.hk
The University of Hong Kong
Interventions
  • Behavioral: Cognitive behavioural therapy-based stepped-care intervention — After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]). Mild symptoms (PHQ-9=5-9): 6 weekly low intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderate symptoms (PHQ-9=10-14): 6 weekly high intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderately severe symptoms (PHQ-9≥15): high intensity individual or group CBT-based intervention. Trained peer supporters will be matched to participants to walk them through the process with regular follow-up.
  • Other: Self-management booklet — The booklet incorporates components of behavioural activation, which encourages participants to engage in meaningful activities in daily life to change their mood. Trained research assistants will regularly check in with the participants to monitor their depressive symptoms.
Study Locations (1 sites)
The University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Currently awaiting psychiatric services provided by the Hospital Authority * Have depressive symptoms of at least mild severity * Able to provide informed consent Exclusion Criteria: * A known history of autism spectrum disorder, intellectual disability, schizophrenia-spectrum disorder, bipolar disorder, Parkinson's disease, or dementia * Imminent suicidal risk (temporary exclusion) * Communication difficulties that preclude participation
Conditions Stress, Emotional, Stress-related Mental...
Phase NA
Enrollment 850
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effectiveness of school-based psychological interventions in improving stress resilience and coping skills among adolescents in rural China. The intervention seeks to reduce stress-related mental health symptoms, including depression, anxiety, and post-traumatic stress, measured using validated instruments such as the Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder 7-item scale (GAD-7), and the Child PTSD Symptom Scale for DSM-5 (CPSS-5). (See Appendix for full scale descriptions.) Participants will be recruited from rural middle schools and randomly assigned to either an intervention group or a wait-list control group. The intervention consists of four sessions delivered over one week. Assessments will be conducted at baseline, immediately after the intervention, and again at a 3-month and 6-month follow-ups. Researchers will use multilevel modeling (MLM) and structural equation modeling (SEM) to examine potential mediators and moderators of intervention effects, including emotion recognition, alexithymia, and coping strategies. indings are expected to provide evidence on the effectiveness and mechanisms of an existing, school-based psychological intervention tailored to the needs of adolescents in underserved rural settings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Psychoeducation — Psychoeducation sessions for adolescents focus on essential topics like stress, emotional distress, and mental disorders, offering foundational knowledge to enhance their understanding and ability to manage these challenges effectively.
  • Behavioral: guided written therapy — In the guided writing intervention, students are asked to write about a recent event that triggered strong emotions on paper and, based on the requirements of each session, attempt to regulate their emotions. This approach aims to enhance students' abilities in emotional identification and emotion regulation.
  • Behavioral: wait-list condition — Participants will engage in their regular school activities, and after the intervention group completes the program, they will receive the same intervention content as the intervention group.

Primary Outcomes

  • PTSD for adolescents (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Depression (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Insomnia Severity (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Generalized anxiety disorder (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Alexithymia (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
  • Emotion awareness (baseline, post treatment (2 weeks after baseline), 3 month after post treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-12
Completion: 2026-12-31
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: true
Enrollment: 850 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Contact Information
Study Contact:
Zang Yinyin, PhD
+86 15553201610
yinyin.zang@pku.edu.cn
Feng Junkai, MSc
86+15625013745
Liang Yachai
86+ 03125217599
Biancun middle school
Interventions
  • Behavioral: Psychoeducation — Psychoeducation sessions for adolescents focus on essential topics like stress, emotional distress, and mental disorders, offering foundational knowledge to enhance their understanding and ability to manage these challenges effectively.
  • Behavioral: guided written therapy — In the guided writing intervention, students are asked to write about a recent event that triggered strong emotions on paper and, based on the requirements of each session, attempt to regulate their emotions. This approach aims to enhance students' abilities in emotional identification and emotion regulation.
  • Behavioral: wait-list condition — Participants will engage in their regular school activities, and after the intervention group completes the program, they will receive the same intervention content as the intervention group.
Study Locations (1 sites)
Biancun middle school, Hebei, Baoding 071603 China
Eligibility Criteria
Inclusion Criteria: * Currently enrolled middle school students attending regular school classes * Sufficient functional capacity in hearing, speaking, reading, and writing to participate in intervention activities and assessments. Exclusion Criteria: * Individuals assessed to be at high risk of suicide, based on screening or clinical judgment * Diagnosis of severe mental disorders (e.g., psychotic disorders, severe mood disorders) that would interfere with participation or require more intensive clinical care
Conditions Uncontrolled Hypertension
Phase PHASE2
Enrollment 280
Locations 24 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if the drug RT-001 works to reduce high blood pressure (hypertension) in adults. It will also learn about the safety of RTN-001. The main questions it aims to answer are: Does RTN-001 lower blood pressure in patients who have uncontrolled hypertension? What medical problems do participants have when taking RTN-001? Researchers will compare RTN-001 to a placebo (a look-alike substance that contains no drug) to see if RTN-001 works to treat uncontrolled hypertension. Participants will: Take RTN-001 or a placebo every day for 12 weeks Visit the clinic about once every 2 weeks for checkups and tests Keep a diary of their symptoms and all medications that they take including RTN-001

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: RTN-001 — A potent and selective PDE5 inhibitor.
  • Drug: Matching placebo control — The reference/comparator product is a matching placebo tablet with similar appearance and weight as the RTN-001 oral tablet.

Primary Outcomes

  • Mean change in systolic blood pressure (SBP) at 4 weeks (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-31
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 280 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Retension Pharmaceuticals. Inc.
Principal Investigators:
  • William CMO, PhD (STUDY_DIRECTOR) - CMO
Contact Information
Study Contact:
Medical Information Information
7036242024
info@retensionpharmaceuticals.com
Bill CMO, PhD
609-651-3773
info@retensionpharmaceuticals.com
CRO Call Center
participate@worldwide.com
Retension Clinical Site
Interventions
  • Drug: RTN-001 — A potent and selective PDE5 inhibitor.
  • Drug: Matching placebo control — The reference/comparator product is a matching placebo tablet with similar appearance and weight as the RTN-001 oral tablet.
Study Locations (24 sites)
Retension Clinical Site, Alexander City, Alabama 35010 United States
Retension Clinical Site, Tucson, Arizona 85715 United States
Retension Clinical Site, San Jose, California 95128 United States
Retension Clinical Site, West Hills, California 91307 United States
Retension Clinical Site, Waterbury, Connecticut 06708 United States
Retension Clinical Site, Orlando, Florida 32801 United States
Retension Clinical Site, Port Orange, Florida 32127 United States
Retension Clinical Site, Tampa, Florida 33606 United States
Retension Clinical Site, Lawrenceville, Georgia 30044 United States
Retension Clinical Site, Peachtree Corners, Georgia 30092 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of written informed consent before any study-specific procedure. 2. Male or female patients age 18 to 75 years, inclusive, at the Screening Visit. 3. Uncontrolled HTN despite being on a stable regimen of 2-5 antihypertensive medications in the following drug classes: ACE-inhibitors, ARBs, beta blockers, calcium channel blockers, mineralocorticoid receptor antagonists, or diuretics. A stable regimen is defined as being on the same medications and the same dose for at least 30 days before screening. A combination pill containing 2 separate classes of antihypertensive drugs is considered 2 antihypertensive medications. 4. Mean BP of ≥ 135/80 mm Hg. 5. Men and nonpregnant, nonlactating women. Women must be either: * Postmenopausal defined as naturally ≥ 1 year without menses or \< 1 year without menses and follicle-stimulating hormone ≥ 40.0 IU/L, or * Surgically sterile including hysterectomy, bilateral oophorectomy, and/or tubal ligation, or Women of childbearing potential must be willing to use 2 acceptable methods of birth control (unless they have agreed to follow the definition of true abstinence). The minimal requirement for adequate contraception should be started the day of Visit T1 (Day 1), continuing during the Treatment Period and for at least 30 days after the last dose of study drug. Acceptable methods of birth control include: * Oral, implantable, injectable, or topical birth control medications. Note: Oral birth control medication must be started ≥ 30 days before the first dose of treatment in the Placebo Run-in. * Placement of an intrauterine device with or without hormones. * Barrier methods including condom or occlusive cap with spermicidal foam or spermicidal jelly. * Vasectomized male partner who is the sole partner for this patient. * True abstinence when this is the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception. 6. Body mass index of 18 to 35 kg/m2. 7. Negative pre-study urine drugs of abuse screen, except for positive findings attributable to medications that are not prohibited (e.g., tetrahydrocannabinol \[THC\]) if prescribed by a physician for an established medical condition and are on a stable dose for at least 4 weeks prior to Screening Visit (S1). 8. If taking a PDE5 inhibitor, must be willing to pause use during the study period. Exclusion Criteria: 1. Currently enrolled in a study with an investigational product or any other type of medical research within 30 days before randomization. 2. Mean seated SBP \> 175 mm Hg and/or DBP \> 110 mm Hg. 3. Current or planned use of nitrates and/or alpha-blockers or other drugs known to affect BP during the study period. 4. Participants who use PDE5 inhibitors for other indications that cannot or will not refrain from use of PDE5 inhibitors for 7 days before and during their entire period of participation in the study. 5. History of hypotension, fainting spells, blackouts or autonomic dysfunction, including orthostatic hypotension. 6. Known diagnosis of secondary hypertension (e.g. Cushing's Disease or hyperaldosteronism, renal fibrodysplasia, renal artery stenosis, etc., clinically significant aortic stenosis etc.). 7. Active pancreatitis. 8. A history of drug abuse. 9. Abuses alcohol defined as average weekly intake greater than 21 units for males or 14 units for females. One unit is equivalent to a 12 oz beer, 1 measure of spirits, or 1 glass of wine. 10. History or presence of gastrointestinal, hepatic, or renal disease or other conditions that would be known to interfere with the absorption, distribution, metabolism, or excretion of drugs. 11. Recent (within 3 months before the Screening Visit \[Visit S1\]) myocardial infarction; unstable angina leading to hospitalization; uncontrolled, symptomatic atrial fibrillation, or any cardiac arrhythmia that has not been clinically stable for at least 3 months prior to the S1 (stability is defined as the absence of new symptoms related to the arrhythmia and no changes in anti-arrhythmic medication or dosage within the 90 days preceding S1); hemodynamically significant aortic stenosis or other clinically significant left ventricular outflow tract obstruction (eg, hypertrophic obstructive cardiomyopathy), coronary artery bypass graft; percutaneous coronary intervention; carotid surgery or stenting; cerebrovascular accident; transient ischemic attack; endovascular procedure or surgical intervention for peripheral vascular disease; or plans to undergo a major surgical or interventional procedure (eg, percutaneous coronary intervention, coronary artery bypass graft, carotid or peripheral revascularization). Participants with implantable pacemakers or automatic implantable cardioverter defibrillators may be considered if deemed by the Investigator to be stable for the previous 3 months. 12. Uncontrolled hypothyroidism, including thyroid-stimulating hormone \> 1.5 × the upper limit of normal (ULN) at the Screening Visit (Visit S1 or Unscheduled visits prior to the T1 visit); patients stabilized on thyroid replacement therapy for at least 6 weeks before randomization are allowed. 13. Liver disease or dysfunction, including: 1. Positive serology for hepatitis B surface antigen and/or hepatitis C antibodies at the Screening Visit (Visit S1 or Unscheduled visits prior to the T1 visit, or 2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≥ 2 × ULN, and/or total bilirubin (TB) ≥ 2 × ULN at the Screening Visit (Visit S1or Unscheduled visits prior to the T1 visit). If TB ≥ 1.2 × ULN, a reflex indirect (unconjugated) bilirubin will be obtained, and if consistent with Gilbert's syndrome or if the patient has a history of Gilbert's syndrome, the patient may be enrolled in the study. Note: At the discretion of the Investigator, a repeat of ALT and/or AST may be completed before randomization. For those patients who have a repeat ALT and/or AST, the repeat value will be used to determine eligibility. Also, if the patient tests positive for the hepatitis C antibody, but the optional reflexive test for hepatitis C RNA is negative, the patient can be enrolled. 14. Renal dysfunction or glomerulonephritis, including estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula \< 45 mL/min/1.73 m2 at the Screening Visit (Visit S1). 15. Active infection or major illness, other than mild viral illness within 30 days prior to T1 visit; positive for HIV antibody. 16. Gastrointestinal conditions or procedures (including weight loss surgery \[eg, Lap-Band or gastric bypass\]) that may affect drug absorption. 17. Hematologic or coagulation disorders or a hemoglobin level \< 10.0 g/dL at the Screening Visit (Visit S1or Unscheduled visits prior to the T1 visit) or anticipated initiation of erythropoietin-stimulating agents and/or planned transfusion within 2 months after screening 18. Active malignancy, including a malignancy requiring surgery, chemotherapy, and/or radiation in the 5 years before Screening. Nonmetastatic basal or squamous cell carcinoma of the skin and cervical carcinoma in situ are allowed. 19. Unexplained creatine kinase (CK) \> 3 × ULN at any time before randomization, which is not associated with recent trauma or physically strenuous activity. Patients with an explained CK elevation must have a single repeat CK ≤ 3 × ULN before randomization. 20. Blood donation, participation in multiple blood draws, clinical study, major trauma, blood transfusion, or surgery with or without blood loss within 30 days before randomization. 21. Use of any experimental or investigational drug(s) within 30 days before the Screening Visit (Visit S1) or for at least five t1/2 lives for investigational biologics (whichever is longer)
Conditions Hypertension
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study will be to analyze the effect of 16 weeks of Yoga training on cardiovascular, autonomic, mental health, and cognitive parameters in hypertensive individuals. This is a randomized, controlled clinical trial to be conducted with adults and elderly (40 years or older), of both sexes, diagnosed with High Blood Pressure (HBP), who will be randomized into two groups: Yoga Group (YG) and Control Group (CG). The YG will undergo a Yoga training program involving breathing techniques, mobility, physical postures, relaxation, and meditation for 16 weeks. In the first eight weeks (phase 1), three supervised weekly sessions will be held. In the last eight weeks of the study (phase 2), the training will consist of three supervised weekly sessions and the delivery of an asynchronous video lesson, with the weekly frequency then increasing (from three to four sessions per week). The video lesson will be available on a digital platform. Before, after eight weeks, and after 16 weeks, cardiovascular, autonomic, mental and cognitive health parameters will be assessed. Furthermore, the biomarkers Brain-Derived Neurotrophic Factor (BDNF), serotonin, and nitric oxide will be analyzed at different assessment times of the study, as well as biochemical profile tests (glucose, total cholesterol, among others), functional capacity tests, and body composition. This project is expected to contribute to the literature by better elucidating the effects of Yoga on the cardiovascular, mental, and cognitive health of hypertensive individuals. The SPSS (21.0) statistical package will be used for data analysis. After confirming the appropriate assumptions, generalized estimating equations will be used, followed by the Bonferroni post hoc test, with a significance level of 5%.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: YOGA — The participants randomized to the yoga group will perform 16 weeks of yoga training, three times/week for 60 minutes.
  • Behavioral: Control — Usual care

Primary Outcomes

  • Blood Pressure (Baseline, 8 and 16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-11
Completion: 2026-12-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidade Federal de Santa Catarina
Contact Information
Study Contact:
Aline Gerage, PhD
554837218554
alinegerage@yahoo.com.br
Aline Gerage, PhD
4899934799
alinegerage@yahoo.com.br
Universidade Federal de Santa Catarina
Interventions
  • Behavioral: YOGA — The participants randomized to the yoga group will perform 16 weeks of yoga training, three times/week for 60 minutes.
  • Behavioral: Control — Usual care
Study Locations (1 sites)
Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina 88040-900 Brazil
Eligibility Criteria
Inclusion Criteria: * Adults or elderly individuals * \>= 40 years * Both sexes * Diagnosis of hypertension controlled by up to three medications * Who do not present high cardiovascular risk * Who have not engaged in a physical exercise program in the six months prior to the start of the study will participate in the study. Exclusion Criteria: * Adherence of less than 75% of training sessions * Diagnosis of other diseases during the study * Adherence to another physical exercise program * Change in the class and/or dose of antihypertensive medication during the study * Worsening of the disease (resting systolic blood pressure (BP) \> 180 mmHg).
Conditions Type 2 Diabetes
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Type 2 diabetes is a major meatbolic condition. People living with Type 2 diabetes come across a wide range of health issues, including psychological health. Specifically, diabetes distress are in high levels among them. Diabetes distress is associated with psychological states such as anxiety, lower levels of self-care, and higher hemoglobin A1c (HbA1c) levels. The Emotional Freedom Technique consists of cognitive and somatic components and is used to heal an individual's negative emotions and manage associated emotional and physical disorders. The basic principle of this technique is to regulate the flow of energy by stimulating the meridian system and to relax the individual while focusing on the emotional reactions that lead to disability. Although the prevalence of psychological problems associated with T2DM and diabetes is increasing, there are not enough studies showing the effect of Emotional Freedom Technique on the psychological well-being of T2DM individuals.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: emotional freedom technique — The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'

Primary Outcomes

  • WHO-5 (Two months)
  • Diabetes Stress Scale (Two months)
  • General Anxiety Scale - 7 (Two months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-06
Completion: 2025-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Uşak University
Contact Information
Study Contact:
Aycan ÇELİK ESMER, PhD
+922122223085
aycan.esmer@usak.edu.tr
Berna DINCER, PhD
berna.dincer@medeniyet.edu.tr
Istanbul Medeniyet University
Interventions
  • Behavioral: emotional freedom technique — The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
Study Locations (1 sites)
Istanbul Medeniyet University, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * being over 18 years of age, * having type 2 diabetes, * no psychiatric diagnosis * agreeing to participate in the study. Exclusion Criteria: * be under 18 years of age, * have type 1 diabetes or gestational diabetes, * attend any course on coping with diabetes distress and anxiety, * have advanced mental health problems.
Conditions Loneliness, Depression, Anxiety
Phase NA
Enrollment 494
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the effectiveness of additional content on loneliness offered alongside the Wellbeing Course - an internet-delivered cognitive behavioral therapy (ICBT) intervention for symptoms of depression and anxiety- in improving treatment outcomes for individuals with elevated scores on loneliness seeking treatment for depression and anxiety at a routine care online therapy clinic (the Online Therapy Unit). In this partially randomized control trial, the investigators aim to contribute to the literature by examining whether providing additional content on loneliness alongside the Wellbeing Course enhances engagement, satisfaction, and treatment outcomes among clients experiencing frequent loneliness compared to those completing only the Wellbeing Course. Over 8 weeks, participants will review course materials (with the addition of the loneliness content for those assigned to the loneliness content condition) online and complete questionnaires assessing changes in various outcomes over time.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Internet-delivered cognitive behavioral therapy — The Wellbeing Course was developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behavioural intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins per week/per client.
  • Behavioral: Additional Loneliness Content — The additional Loneliness Content was developed at the Online Therapy Unit, University of Regina, Canada. Relevant sections of the resource will be included at the end of each lesson within the Wellbeing Course. The Loneliness Content provides psychoeducation and skills for loneliness using a cognitive behavioral framework. Consistent with the Wellbeing Course content, the Loneliness Content will target 1) identification of loneliness; 2) loneliness thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling for loneliness; 4) behaviours (conversation skills); and 5) relapse prevention.

Primary Outcomes

  • UCLA Loneliness Scale 3-item (UCLA-3) (Baseline (Screening), weeks 4, 8 and 20 from enrollment)
  • Patient Health Questionnaire - 9 (PHQ-9) (Baseline (Screening), weeks 1-8 and 20 from enrollment)
  • Generalized Anxiety Disorder - 7 (GAD-7) (Baseline (Screening), weeks 1-8 and 20 from enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-18
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 494 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Regina
Collaborators: Government of Saskatchewan, Ministry of Health, Linkoeping University, Macquarie University, Australia
Principal Investigators:
  • Heather Hadjistavropoulos, PhD (PRINCIPAL_INVESTIGATOR) - University of Regina
Contact Information
Study Contact:
Marcie Nugent, MSW
306-337-3331
marcie.nugent@uregina.ca
Heather Hadjistavropoulos, PhD
306-585-5133
heather.hadjistavropoulos@uregina.ca
Marcie Nugent, MSW
306-337-3331
marcie.nugent@uregina.ca
Online Therapy Unit
Interventions
  • Behavioral: Internet-delivered cognitive behavioral therapy — The Wellbeing Course was developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behavioural intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins per week/per client.
  • Behavioral: Additional Loneliness Content — The additional Loneliness Content was developed at the Online Therapy Unit, University of Regina, Canada. Relevant sections of the resource will be included at the end of each lesson within the Wellbeing Course. The Loneliness Content provides psychoeducation and skills for loneliness using a cognitive behavioral framework. Consistent with the Wellbeing Course content, the Loneliness Content will target 1) identification of loneliness; 2) loneliness thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling for loneliness; 4) behaviours (conversation skills); and 5) relapse prevention.
Study Locations (2 sites)
Online Therapy Unit, Regina, Saskatchewan S4S 0A2 Canada
Online Therapy Unit, Regina, Saskatchewan S4S0A2 Canada
Eligibility Criteria
Inclusion Criteria: * Saskatchewan resident, * Aged 18 years or older, * Self-reported difficulty with depression and/or anxiety, * Access to a computer (or other appropriate device) and the Internet, * Willingness to learn information and skills to self-manage mental health difficulties, and * Total score on UCLA-3 is greater than 5 at screening Exclusion Criteria: * Current severe medical or psychiatric condition that requires immediate treatment (e.g. current mania or psychosis, actively suicidal or unable to keep themselves safe, medical condition requiring immediate surgery or other invasive treatment); * Unable to read and understand English (All content is provided in English and staff is English speaking)
Conditions Asthma Attack, Lung Function, Airway Inf...
Phase NA
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This project will investigate the effectiveness of HEPA air cleaners in reducing indoor air pollution and improving asthma morbidity in children living in East Harlem, New York City (NYC). The study will be conducted over a 2-year period. Columbia University and Little Sisters of the Assumption Family Health Service (LSAFHS) will conduct an intervention study to evaluate the efficacy of using a cost-effective high-capacity high efficiency particulate air (HEPA) filter air cleaner to reduce airborne particulate matter (PM) in the homes of children with asthma and to reduce their asthma morbidity. The study will take place in East Harlem, a low-income neighborhood with high asthma prevalence. It will build on findings from prior Housing and Urban Development Lead and Healthy Homes Technical Studies (HUD LHHTS)-funded research, the experience of LSAFHS installing air cleaners in the homes of asthmatic children, and recent findings demonstrating the effectiveness of home air cleaners in reducing asthma morbidity. The investigators hypothesize that the cost-effective single air cleaner will substantially reduce PM exposure in the homes of asthmatic children and reduce airway inflammation and asthma morbidity. This study will use cutting-edge air sampling technology to continuously quantify and characterize indoor air pollutants in the home for one year, verify and incentivize compliance, and conduct repeated exhaled nitric oxide and pulmonary function tests before and throughout the year after the intervention. This cost-effective intervention can be easily and quickly implemented in homes in low-income, urban communities and easily transferred between homes if families move.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Austin Air Cleaner — The Austin Air Purifier consists of 4 stages, a large particle pre-filter, medium pre-filter, a medical grade HEPA filter and a high efficiency gas arrestance carbon cloth to reduce air pollution in homes.

Primary Outcomes

  • Fractional Exhaled Nitric Oxide (FeNO) (1 week before, immediately before, two weeks after, and one year after the air cleaner is turned on.)
  • Forced Expiratory Volume in 1 Second/ Forced Vital Capacity (FEV1/FVC) Ratio (1 week before, immediately before, two weeks after, then once a month (up to 1 year) after the air cleaner is turned on.)
  • Number of Attacks of Wheezing (Once per month for up to 12 months after the air cleaner is turned on)
  • Number of Emergency Department (ED) Visits (12 months after the air cleaner is turned on)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-30
Completion: 2028-04
Eligibility
Age: 7 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: Little Sisters of the Assumption Family Health Service
Principal Investigators:
  • Matthew S Perzanowski, PhD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Matthew S Perzanowski, PhD
(212) 305-3465
mp2217@cumc.columbia.edu
Luis M Acosta, MD
(212) 305-6925
la181@cumc.columbia.edu
Interventions
  • Device: Austin Air Cleaner — The Austin Air Purifier consists of 4 stages, a large particle pre-filter, medium pre-filter, a medical grade HEPA filter and a high efficiency gas arrestance carbon cloth to reduce air pollution in homes.
Study Locations (1 sites)
Columbia University Irving Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Age 7-18 years * Asthma symptoms in the past 4 weeks * Resident in lower-income housing in NYC Northern Manhattan and South Bronx Exclusion Criteria: * Inability to successfully perform spirometry maneuver or FeNO test * Family planning to move in the next year
Conditions Depression, Postpartum, Anxiety, Pregnan...
Phase NA
Enrollment 570
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression, anxiety, and related disorders such as post-traumatic stress and obsessive compulsive disorder affect about 20% of pregnant and postpartum people. When not treated properly, these issues negatively impact not only affected people, but also their children's health and development. Only 1 in 5 receive adequate treatment, so identifying new system-wide approaches to reliably deliver recommended care to perinatal mental health patients all is a crucial health care priority. The Pregnancy and Postpartum Mental health Optimization Virtual Intervention Network (MOVIN) is a scalable perinatal mental health platform building on the evidence-based Collaborative care delivery model. MOVIN's online platform allows patients to connect with a care coordinator to co-develop personalized treatment recommendations, in collaboration with their primary care clinician and a perinatal psychiatrist when needed; progress is tracked to re-evaluate.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Enhanced Usual Care — Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
  • Other: MOVIN Care Platform — Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
  • Other: Enhanced Usual Care — Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.

Primary Outcomes

  • Depressive symptoms (24 weeks post randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-29
Completion: 2029-03-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 570 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Women's College Hospital
Collaborators: Sunnybrook Health Sciences Centre, Mount Sinai Hospital, Canada, The Ottawa Hospital, St. Joseph's Healthcare Hamilton
Contact Information
Study Contact:
Simone Vigod
416-323-6400
simone.vigod@wchospital.ca
Interventions
  • Other: Enhanced Usual Care — Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
  • Other: MOVIN Care Platform — Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
  • Other: Enhanced Usual Care — Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
Study Locations (2 sites)
Women's College Hospital, Toronto, Ontario M5S 1B2 Canada
Women's College Hospital, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: 1. Adult (age 18 years or older) 2. Pregnant or postpartum and living with their infant 0-6 months old. This includes all individuals who identify as women, as well as those of female sex who do not identify as women (e.g., non-binary, trans) who are the primary parent for their infant. This includes via natural birth, adoption, or surrogacy. 3. EPDS score \>10 at eligibility screening. Exclusion Criteria: 1. Active alcohol or substance use disorder, mania or psychotic disorder (as these conditions are better managed in direct specialty care). 2. Active suicide plan or intent (as emergent hospital-based care is likely required), 3. Plan to move out of Ontario during the study. 4. Unable to complete relevant study procedures and measures online. For the few participants without access to devices/home internet, we will budget for tablets/data plans. 5. Unable to complete study activities in English. Note that Google translate is available for the intervention platform and language lines are available for participants so that they can be served in their language of choice, however we are unable to provide translations of all study assessment and questionnaire materials that participants will need to complete during the study. 6. No primary care clinician (required for collaborative mental health care delivery model). 7. Currently enrolled in a collaborative mental health care model.
Conditions Type 2 Diabetes Mellitus - Poor Control
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes. People in the study will join group visits virtually to discuss using CGM, understanding CGM, and other information about ways to bring blood sugars to your goal (nutrition, movement, reducing stress, and techniques to start a new habit).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Education, lifestyle counseling, and peer support — This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes. People in the study will join group visits virtually to discuss using CGM, understanding CGM, and other information about ways to bring blood sugars to your goal (nutrition, movement, reducing stress, and techniques to start a new habit).

Primary Outcomes

  • Hemoglobin A1c (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-01
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Whole Endo
Collaborators: DexCom, Inc.
Contact Information
Study Contact:
Rashim Gupta, MD
980-349-6036
rashim.gupta@wholeendo.com
Javier Samayoa, EdD
javier.samayoa@wholeendo.com
Interventions
  • Behavioral: Education, lifestyle counseling, and peer support — This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes. People in the study will join group visits virtually to discuss using CGM, understanding CGM, and other information about ways to bring blood sugars to your goal (nutrition, movement, reducing stress, and techniques to start a new habit).
Study Locations (1 sites)
Whole Endo, Asheville, North Carolina 28801 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Diagnosed with type 2 diabetes mellitus Hemoglobin A1c \>8% Must have smartphone to connect with continuous glucose monitor Exclusion Criteria: * Pregnancy Use of steroids Active cancer treatment Terminal illness Dementia, mental impairment Type 1 diabetes End stage renal disease, on dialysis